On the public citation graph
Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)
0 signed · 342 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1001/jamaoncol.2018.0013openalex-snapshot
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer
inferredcites →https://doi.org/10.1007/s10147-014-0701-7openalex-snapshot
Expression of costimulatory molecules B7-H1, B7-H4 and Foxp3+ Tregs in gastric cancer and its clinical significance
inferredcites →https://doi.org/10.1016/j.ejca.2008.10.026openalex-snapshot
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
inferredcites →https://doi.org/10.1016/j.ejca.2011.12.017openalex-snapshot
A randomized phase II trial of S-1-oxaliplatin versus capecitabine–oxaliplatin in advanced gastric cancer
inferredcites →https://doi.org/10.1016/s0140-6736(10)61121-xopenalex-snapshot
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
inferredcites →https://doi.org/10.1016/s0140-6736(13)61719-5openalex-snapshot
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
inferredcites →https://doi.org/10.1016/s0140-6736(17)31827-5openalex-snapshot
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
inferredcites →https://doi.org/10.1016/s1470-2045(13)70436-4openalex-snapshot
Management of gastric cancer in Asia: resource-stratified guidelines
inferredcites →https://doi.org/10.1016/s1470-2045(14)70420-6openalex-snapshot
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
inferredcites →https://doi.org/10.1038/nri2216openalex-snapshot
Immunological aspects of cancer chemotherapy
inferredcites →https://doi.org/10.1056/nejmoa073149openalex-snapshot
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
inferredcites →https://doi.org/10.1056/nejmoa1504030openalex-snapshot
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
inferredcites →https://doi.org/10.1056/nejmoa1504627openalex-snapshot
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1056/nejmoa1507643openalex-snapshot
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1056/nejmoa1510665openalex-snapshot
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
inferredcites →https://doi.org/10.1056/nejmoa1602252openalex-snapshot
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
inferredcites →https://doi.org/10.1093/annonc/mdn717openalex-snapshot
Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial
inferredcites →https://doi.org/10.1093/annonc/mdp047openalex-snapshot
Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer
inferredcites →https://doi.org/10.1093/annonc/mdq164openalex-snapshot
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
inferredcites →https://doi.org/10.1093/annonc/mdu472openalex-snapshot
Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer
inferredcites →https://doi.org/10.1093/annonc/mdw350openalex-snapshot
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
inferredcites →https://doi.org/10.1126/scitranslmed.aad7118openalex-snapshot
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
inferredcites →https://doi.org/10.1158/1078-0432.ccr-13-3141openalex-snapshot
Molecular Pathways: The Immunogenic Effects of Platinum-Based Chemotherapeutics
inferredcites →https://doi.org/10.1159/000455014openalex-snapshot
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
inferredcites →https://doi.org/10.1200/edbk_175228openalex-snapshot
Gastric Cancer in Asia: Unique Features and Management
inferredcites →https://doi.org/10.1200/jco.2006.06.8429openalex-snapshot
Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group
inferredcites →https://doi.org/10.1200/jco.2016.66.9861openalex-snapshot
Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1200/jco.2017.76.6212openalex-snapshot
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
inferredcites →https://doi.org/10.1200/jco.2018.36.4_suppl.5openalex-snapshot
RAINFALL: A randomized, double-blind, placebo-controlled phase III study of cisplatin (Cis) plus capecitabine (Cape) or 5FU with or without ramucirumab (RAM) as first-line therapy in patients with metastatic gastric or gastroesophageal junction (G-GEJ) adenocarcinoma.
inferredcites →https://doi.org/10.4103/2319-4170.117887openalex-snapshot
Modified Biweekly Oxaliplatin and Capecitabine for Advanced Gastric Cancer: A Retrospective Analysis from a Medical Center
inferredcites →https://doi.org/10.6004/jnccn.2016.0137openalex-snapshot
Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4111359openalex-extracted
Anti Pd-1 /Anti Pdl-1 Inhibitors in Advanced Gastroesophageal Cancers: A Systematic Review and Meta-Analysis of Phase 2/3 Randomized Controlled Trials
inferred← citeshttps://doi.org/10.1002/ags3.70103openalex-snapshot
Unexpectedly High Incidence of Immune‐Related Adverse Events in Gastric Cancer Patients Who Received Conversion Surgery After Nivolumab‐Including Chemotherapy
inferred← citeshttps://doi.org/10.1002/ags3.70188openalex-snapshot
Comparison Between Upfront Surgery and Preoperative Chemotherapy for CY1P0 Gastric Cancer: A Japanese Sub‐Analysis of CONVO ‐ GC ‐1
inferred← citeshttps://doi.org/10.1002/cam4.4461openalex-snapshot
Prognostic factors to predict the survival in patients with advanced gastric cancer who receive later‐line nivolumab monotherapy—The Asahikawa Gastric Cancer Cohort Study (AGCC)
inferred← citeshttps://doi.org/10.1002/jso.26874openalex-snapshot
Molecular pathogenesis and emerging targets of gastric adenocarcinoma
inferred← citeshttps://doi.org/10.1007/978-3-030-48405-7_8openalex-snapshot
Emerging Roles of Phytochemicals in the Pathobiology and Management of Esophageal Cancer
inferred← citeshttps://doi.org/10.1007/978-3-030-73158-8_28openalex-snapshot
Target Therapy and Immunotherapy in Gastric Cancer
inferred← citeshttps://doi.org/10.1007/s00018-022-04129-0openalex-snapshot
METTL3 promotes oxaliplatin resistance of gastric cancer CD133+ stem cells by promoting PARP1 mRNA stability
inferred← citeshttps://doi.org/10.1007/s00262-022-03174-9openalex-snapshot
Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study
inferred← citeshttps://doi.org/10.1007/s00262-025-04161-6openalex-snapshot
Immune checkpoint inhibitors combined with chemotherapy in conversion therapy for stage IV gastric cancer: a multicenter retrospective cohort study
inferred← citeshttps://doi.org/10.1007/s00280-025-04817-1openalex-snapshot
Synergistic interactions and optimal sequencing of chemotherapy and immunotherapy in cancer treatment
inferred← citeshttps://doi.org/10.1007/s00428-023-03623-5openalex-snapshot
Clinicopathological characteristics of gastric adenocarcinoma with enteroblastic differentiation and gastric adenocarcinoma with enteroblastic marker expression
inferred← citeshttps://doi.org/10.1007/s00432-021-03896-wopenalex-snapshot
Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial
inferred← citeshttps://doi.org/10.1007/s00432-021-03902-1openalex-snapshot
Evolution of predictive and prognostic biomarkers in the treatment of advanced gastric cancer
inferred← citeshttps://doi.org/10.1007/s00520-021-06557-3openalex-snapshot
Risk factors and characteristics of bacterial infection during first-line chemotherapy for metastatic gastric or gastroesophageal junction adenocarcinoma
inferred← citeshttps://doi.org/10.1007/s00595-020-02048-wopenalex-snapshot
Systemic inflammatory response and nutritional biomarkers as predictors of nivolumab efficacy for gastric cancer
inferred← citeshttps://doi.org/10.1007/s00595-023-02773-yopenalex-snapshot
Current status of vaccine immunotherapy for gastrointestinal cancers
inferred← citeshttps://doi.org/10.1007/s10120-020-01137-6openalex-snapshot
Impact of preoperative chemotherapy as initial treatment for advanced gastric cancer with peritoneal metastasis limited to positive peritoneal lavage cytology (CY1) or localized peritoneal metastasis (P1a): a multi-institutional retrospective study
inferred← citeshttps://doi.org/10.1007/s10120-023-01431-zopenalex-snapshot
SOX combined with sintilimab versus SOX alone in the perioperative management of locally advanced gastric cancer: a propensity score–matched analysis
inferred← citeshttps://doi.org/10.1007/s10120-025-01683-xopenalex-snapshot
Safety, survival outcomes, and prognostic factors in conversion surgery for advanced gastric cancer: a sub-analysis of Japanese patients in the CONVO-GC-1 study
inferred← citeshttps://doi.org/10.1007/s10147-023-02402-1openalex-snapshot
Meta-analysis of three randomized trials of capecitabine plus cisplatin (XP) versus S-1 plus cisplatin (SP) as first-line treatment for advanced gastric cancer
inferred← citeshttps://doi.org/10.1007/s10147-025-02748-8openalex-snapshot
A multicenter randomized open-label phase 2 study investigating optimal antiemetic therapy for patients with advanced/recurrent gastric cancer treated with trastuzumab deruxtecan: the EN-hance study
inferred← citeshttps://doi.org/10.1007/s10147-025-02804-3openalex-snapshot
Impact of cancer type differences on chemotherapy-induced nausea and vomiting (CINV) incidence in oxaliplatin-based regimens for gastric and colorectal cancer: a retrospective study
inferred← citeshttps://doi.org/10.1007/s10147-025-02888-xopenalex-snapshot
FLOT vs DOS neoadjuvant chemotherapy in locally advanced gastric cancer: propensity score analysis
inferred← citeshttps://doi.org/10.1007/s12029-025-01172-5openalex-snapshot
Nivolumab Combined with Chemotherapy in FGFR2 and PD-L1 Co-Expressing Metastatic Gastric Cancer: A Prospective Phase 2 NIVOFGFR2 Study
inferred← citeshttps://doi.org/10.1007/s12029-025-01211-1openalex-snapshot
The Efficacy and Safety of Nivolumab Combined with Nab-Paclitaxel or Oxaliplatin as a First-Line Treatment for Advanced or Metastatic Gastric Cancer and Gastroesophageal Junction Cancer
inferred← citeshttps://doi.org/10.1007/s12029-025-01215-xopenalex-snapshot
Combined Chemotherapy-Immunotherapy for Advanced Biliary Tract Cancer (BTC): A Clinical, Genomic, and Biomarker Analysis
inferred← citeshttps://doi.org/10.1007/s12094-021-02760-0openalex-snapshot
Current status and future perspectives in HER2 positive advanced gastric cancer
inferred← citeshttps://doi.org/10.1007/s12094-023-03181-xopenalex-snapshot
Immune checkpoint inhibitors and cellular immunotherapy for advanced gastric, gastroesophageal cancer: a long pathway
inferred← citeshttps://doi.org/10.1007/s12328-023-01886-8openalex-snapshot
Gastric cancer with Fanconi anemia in adolescent and young adult patient diagnosed by comprehensive genome profiling using next-generation sequencing
inferred← citeshttps://doi.org/10.1007/s12672-023-00807-yopenalex-snapshot
Integrated analysis of single-cell and bulk RNA-sequencing reveals the poor prognostic value of ABCA1 in gastric adenocarcinoma
inferred← citeshttps://doi.org/10.1007/s13402-019-00488-2openalex-snapshot
Esophageal carcinoma: Towards targeted therapies
inferred← citeshttps://doi.org/10.1007/s13402-024-01021-wopenalex-snapshot
Toxicity profiles of immunochemotherapy for gastric or gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1007/s44178-024-00074-zopenalex-snapshot
Changes in the neutrophil-to-lymphocyte ratio (NLR) as predictive values for metastatic gastric cancer patients with PD-1 inhibitors
inferred← citeshttps://doi.org/10.1007/s44178-025-00220-1openalex-snapshot
Post-gastric cancer surgery hypophysitis and cortisol insufficiency after immunotherapy: a case series
inferred← citeshttps://doi.org/10.1016/b978-0-12-800684-9.00009-5openalex-snapshot
Esophageal and gastric cancer
inferred← citeshttps://doi.org/10.1016/j.annonc.2021.02.004openalex-snapshot
Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy
inferred← citeshttps://doi.org/10.1016/j.annonc.2021.03.203openalex-snapshot
Distinct genomic landscapes of gastroesophageal adenocarcinoma depending on PD-L1 expression identify mutations in RAS–MAPK pathway and TP53 as potential predictors of immunotherapy efficacy
inferred← citeshttps://doi.org/10.1016/j.bbadis.2024.167019openalex-snapshot
Dawn era for revisited cancer therapy by innate immune system and immune checkpoint inhibitors
inferred← citeshttps://doi.org/10.1016/j.biopha.2020.110504openalex-snapshot
Research progress of PD-1/PD-L1 immunotherapy in gastrointestinal tumors
inferred← citeshttps://doi.org/10.1016/j.canlet.2019.10.036openalex-snapshot
PD-1 and PD-L1 inhibitors in oesophago-gastric cancers
inferred← citeshttps://doi.org/10.1016/j.clnu.2023.11.009openalex-snapshot
Sarcopenia affects the clinical efficacy of immune checkpoint inhibitors in patients with gastrointestinal cancers
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2020.103173openalex-snapshot
A systematic review and meta-analysis of PD-1/PD-L1 inhibitors in specific patient subgroups with advanced gastro-oesophageal junction and gastric adenocarcinoma
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2025.104908openalex-snapshot
Chemotherapy modulates PD-L1 expression and its combination with immune checkpoint blockade requires precision
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2026.105166openalex-snapshot
Neoadjuvant PD-1/PD-L1 inhibitors plus chemotherapy in locally advanced gastric cancer: A systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1016/j.ctarc.2026.101476openalex-snapshot
CAD potentially mediates 5‑fluorouracil resistance in gastric cancer cells via modulation of uridine monophosphate synthetase expression
inferred← citeshttps://doi.org/10.1016/j.ctrv.2019.101889openalex-snapshot
Gastric cancer: Translating novels concepts into clinical practice
inferred← citeshttps://doi.org/10.1016/j.ctrv.2021.102289openalex-snapshot
Advanced oesophago-gastric adenocarcinoma in older patients in the era of immunotherapy. A review of the literature
inferred← citeshttps://doi.org/10.1016/j.ctrv.2023.102542openalex-snapshot
Comprehensive evaluation of surrogate endpoints to predict overall survival in trials with PD1/PD-L1 immune checkpoint inhibitors plus chemotherapy
inferred← citeshttps://doi.org/10.1016/j.dld.2020.11.036openalex-snapshot
PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer
inferred← citeshttps://doi.org/10.1016/j.eclinm.2023.102156openalex-snapshot
Intermediate endpoints as surrogates for outcomes in cancer immunotherapy: a systematic review and meta-analysis of phase 3 trials
inferred← citeshttps://doi.org/10.1016/j.ejca.2019.09.006openalex-snapshot
Multidisciplinary management of stage II-III gastric and gastro-oesophageal junction cancer
inferred← citeshttps://doi.org/10.1016/j.ejca.2020.02.002openalex-snapshot
Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study
inferred← citeshttps://doi.org/10.1016/j.ejca.2022.08.023openalex-snapshot
Recent progress and current challenges of immunotherapy in advanced/metastatic esophagogastric adenocarcinoma
inferred← citeshttps://doi.org/10.1016/j.ejmg.2022.104475openalex-snapshot
Solving the genetic aetiology of hereditary gastrointestinal tumour syndromes– a collaborative multicentre endeavour within the project Solve-RD
inferred← citeshttps://doi.org/10.1016/j.esmoop.2026.108536openalex-snapshot
Pembrolizumab plus chemotherapy as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: 4.5-year follow-up from the randomized phase III KEYNOTE-859 study
inferred← citeshttps://doi.org/10.1016/j.ijscr.2021.106161openalex-snapshot
Clinical complete response after nivolumab administered as a third-line treatment for unresectable advanced gastric cancer with peritoneal dissemination: A case report
inferred← citeshttps://doi.org/10.1016/j.jgo.2021.09.006openalex-snapshot
Gastroesophageal adenocarcinoma in older adults: A comprehensive narrative review of management by the Young International Society of Geriatric Oncology
inferred← citeshttps://doi.org/10.1016/j.jtho.2020.01.017openalex-snapshot
Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC
inferred← citeshttps://doi.org/10.1016/j.mucimm.2024.03.007openalex-snapshot
Interaction of microbiota, mucosal malignancies, and immunotherapy—Mechanistic insights
inferred← citeshttps://doi.org/10.1016/j.prp.2020.153322openalex-snapshot
Immunotherapy of gastric cancer: Past, future perspective and challenges
inferred← citeshttps://doi.org/10.1016/j.prp.2022.154110openalex-snapshot
Common strategies for effective immunotherapy of gastroesophageal cancers using immune checkpoint inhibitors
inferred← citeshttps://doi.org/10.1016/j.resinv.2021.11.014openalex-snapshot
Predictive role of CYFRA 21-1 for S-1 monotherapy in non-small cell lung cancer patients
inferred← citeshttps://doi.org/10.1016/j.scib.2023.03.011openalex-snapshot
Conversion therapy for stage IV gastric cancer
inferred← citeshttps://doi.org/10.1016/j.xcrm.2025.102145openalex-snapshot
Benmelstobart plus anlotinib and chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: A phase 2 study
inferred← citeshttps://doi.org/10.1016/j.xinn.2020.100041openalex-snapshot
Current Status and Future Perspective of Immunotherapy in Gastrointestinal Cancers
inferred← citeshttps://doi.org/10.1016/j.yao.2021.02.008openalex-snapshot
Expanding the Role of Checkpoint Inhibitors in Immune Cold Tumors
inferred← citeshttps://doi.org/10.1016/s1470-2045(21)00692-6openalex-snapshot
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
inferred← citeshttps://doi.org/10.1021/acsami.2c14448openalex-snapshot
Inflammation-Regulated Nanodrug Sensitizes Hepatocellular Carcinoma to Checkpoint Blockade Therapy by Reprogramming the Tumor Microenvironment
inferred← citeshttps://doi.org/10.1021/acsptsci.4c00677openalex-snapshot
Innovative Immunotherapy and Its Transformative Impact on Gastric Adenocarcinoma: A Comprehensive Review of the Disease’s Origins, Epidemiology, Classification, Diagnosis, and Treatment Options
inferred← citeshttps://doi.org/10.1038/s41392-021-00771-5openalex-snapshot
ASTE1 frameshift mutation triggers the immune response in Epstein-Barr virus-associated gastric cancer
inferred← citeshttps://doi.org/10.1038/s41392-022-01080-1openalex-snapshot
Hypoxia signaling in human health and diseases: implications and prospects for therapeutics
inferred← citeshttps://doi.org/10.1038/s41392-023-01622-1openalex-snapshot
Dynamic single-cell mapping unveils Epstein‒Barr virus-imprinted T-cell exhaustion and on-treatment response
inferred← citeshttps://doi.org/10.1038/s41416-022-01751-4openalex-snapshot
Immunotherapy use in oesophagogastric cancers—a review of the literature
inferred← citeshttps://doi.org/10.1038/s41416-025-03033-1openalex-snapshot
Determining the optimal duration of oral adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma
inferred← citeshttps://doi.org/10.1038/s41467-020-19949-6openalex-snapshot
Genomic and transcriptomic alterations associated with drug vulnerabilities and prognosis in adenocarcinoma at the gastroesophageal junction
inferred← citeshttps://doi.org/10.1038/s41598-020-66637-yopenalex-snapshot
Observational Study of Peritoneal Washing Cytology-Positive Gastric Cancer without Gross Peritoneal Metastasis in Patients who Underwent Radical D2 Gastrectomy
inferred← citeshttps://doi.org/10.1038/s41598-020-71340-zopenalex-snapshot
Distinct tumor immune microenvironments in primary and metastatic lesions in gastric cancer patients
inferred← citeshttps://doi.org/10.1038/s41598-022-24426-9openalex-snapshot
Comparative efficacy and tolerability of targeted and immunotherapy combined with chemotherapy as first-line treatment for advanced gastric cancer: a Bayesian network meta-analysis
inferred← citeshttps://doi.org/10.1038/s41598-023-46933-zopenalex-snapshot
Early detection of brain metastases and appropriate local therapy followed by systemic chemotherapy may improve the prognosis of gastric cancer
inferred← citeshttps://doi.org/10.1038/s41598-026-51753-yopenalex-snapshot
Mechanistic study of TIMM44 mediating gastric carcinogenesis via the Gαi1-PI3K-AKT-mTOR signaling pathway
inferred← citeshttps://doi.org/10.1053/j.gastro.2020.10.036openalex-snapshot
PD-1 Signaling Promotes Tumor-Infiltrating Myeloid-Derived Suppressor Cells and Gastric Tumorigenesis in Mice
inferred← citeshttps://doi.org/10.1080/14728214.2021.2020757openalex-snapshot
Recent advances in immune-based approaches for the treatment of esophagogastric cancer
inferred← citeshttps://doi.org/10.1080/14737140.2022.2139241openalex-snapshot
Nivolumab with or without chemotherapy for metastatic gastroesophageal cancers and future perspectives
inferred← citeshttps://doi.org/10.1080/17512433.2021.1938546openalex-snapshot
Comparing immunotherapies to other frequently used treatments of gastric cancer
inferred← citeshttps://doi.org/10.1080/2162402x.2019.1581547openalex-snapshot
Efficacy and safety of immune checkpoint inhibitors in advanced gastric or gastroesophageal junction cancer: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1080/2162402x.2020.1862520openalex-snapshot
M1-like TAMs are required for the efficacy of PD-L1/PD-1 blockades in gastric cancer
inferred← citeshttps://doi.org/10.1080/2162402x.2020.1864908openalex-snapshot
Anti-PD-1 antibody HX008 combined with oxaliplatin plus capecitabine for advanced gastric or esophagogastric junction cancer: a multicenter, single-arm, open-label, phase Ib trial
inferred← citeshttps://doi.org/10.1080/2162402x.2021.1960729openalex-snapshot
PD-1 inhibition in patient derived tissue cultures of human gastric and gastroesophageal adenocarcinoma
inferred← citeshttps://doi.org/10.1089/cbr.2020.3643openalex-snapshot
Synergism Between Immunotherapy and Radiotherapy in Esophageal Cancer: An Overview of Current Knowledge and Future Perspectives
inferred← citeshttps://doi.org/10.1093/annonc/mdy555openalex-snapshot
Is front-line checkpoint blockade ATTRACTIVE in advanced gastric cancer?
inferred← citeshttps://doi.org/10.1093/annonc/mdz197openalex-snapshot
Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432
inferred← citeshttps://doi.org/10.1093/carcin/bgac043openalex-snapshot
CSF-1R inhibitor, pexidartinib, sensitizes esophageal adenocarcinoma to PD-1 immune checkpoint blockade in a rat model
inferred← citeshttps://doi.org/10.1093/oncolo/oyae109openalex-snapshot
A phase 1 study of biweekly nab-paclitaxel/oxaliplatin/S-1/LV for advanced upper gastrointestinal cancers: TCOG T1216 study
inferred← citeshttps://doi.org/10.1097/cco.0000000000000859openalex-snapshot
Mind the target: programmed death ligand 1 in oesophagogastric cancers
inferred← citeshttps://doi.org/10.1097/cm9.0000000000002185openalex-snapshot
Research progress in targeted therapy and immunotherapy for gastric cancer
inferred← citeshttps://doi.org/10.1097/cm9.0000000000004095openalex-snapshot
Conversion surgery after immunotherapy and chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology: A retrospective cohort study
inferred← citeshttps://doi.org/10.1097/cm9.0000000000004194openalex-snapshot
Molecular mechanisms, current therapeutics, and emerging strategies in esophageal cancer: A comprehensive review
inferred← citeshttps://doi.org/10.1097/jcma.0000000000000922openalex-snapshot
Immunoprofile of adenosquamous carcinoma in gastric cancer
inferred← citeshttps://doi.org/10.1097/md.0000000000018054openalex-snapshot
Efficacy and safety of anti-PD-1/PD-L1 agents vs chemotherapy in patients with gastric or gastroesophageal junction cancer: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1097/md.0000000000029304openalex-snapshot
The current management and biomarkers of immunotherapy in advanced gastric cancer
inferred← citeshttps://doi.org/10.1097/md.0000000000029802openalex-snapshot
Clinical significance and prospective molecular mechanism of NUF2 in gastric cancer exploration: A comprehensive study based on the GeneChip, GEO, Oncomine, and TCGA databases
inferred← citeshttps://doi.org/10.1097/md.0000000000033377openalex-snapshot
Immune checkpoint inhibitors are effective in the treatment of Epstein-Barr virus-associated gastric cancer: A case report
inferred← citeshttps://doi.org/10.1097/mog.0000000000000542openalex-snapshot
The emerging role of immunotherapy for esophageal cancer
inferred← citeshttps://doi.org/10.1111/1346-8138.16614openalex-snapshot
Skin rash associated with combined cytotoxic chemotherapy and immunotherapy for cancer: A retrospective single‐center case series
inferred← citeshttps://doi.org/10.1111/hel.12878openalex-snapshot
Influence of Helicobacter pylori infection on PD‐1/PD‐L1 blockade therapy needs more attention
inferred← citeshttps://doi.org/10.1111/his.14244openalex-snapshot
Targeted therapy for upper gastrointestinal tract cancer: current and future prospects
inferred← citeshttps://doi.org/10.1136/esmoopen-2019-000595openalex-snapshot
Single-institute comparison of the efficacy of systemic chemotherapy for oesophagogastric junction adenocarcinoma and stomach adenocarscinoma in a metastatic setting
inferred← citeshttps://doi.org/10.1136/esmoopen-2020-000791openalex-snapshot
Current status and future potential of predictive biomarkers for immune checkpoint inhibitors in gastric cancer
inferred← citeshttps://doi.org/10.1136/jitc-2019-000173openalex-snapshot
Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer
inferred← citeshttps://doi.org/10.1136/jitc-2022-004487openalex-snapshot
Pathological complete response to immune checkpoint inhibitor in patients with colorectal cancer liver metastases harboring POLE exonuclease domain mutation
inferred← citeshttps://doi.org/10.1155/2021/2549295openalex-snapshot
Neutrophil-to-Lymphocyte Ratio (NLR) Predicts PD-1 Inhibitor Survival in Patients with Metastatic Gastric Cancer
inferred← citeshttps://doi.org/10.1155/2022/3445230openalex-snapshot
Comprehensive Analysis of the Immune Implication of AKAP12 in Stomach Adenocarcinoma
inferred← citeshttps://doi.org/10.1155/2022/5415758openalex-snapshot
Delineating Molecular Subtypes through Gene Set Variation Analysis Confers Therapeutic and Prognostic Capability in Gastric Cancer
inferred← citeshttps://doi.org/10.1155/2023/4946642openalex-snapshot
Meta‐Analysis of Capecitabine versus 5‐Fluorouracil in Advanced Gastric Cancer
inferred← citeshttps://doi.org/10.1155/2024/5599162openalex-snapshot
The Evaluation for Expandable Applications of Tislelizumab in First‐Line Treatment for Advanced Gastric Cancer
inferred← citeshttps://doi.org/10.11569/wcjd.v31.i15.647openalex-snapshot
Carrilizumab for treatment of advanced colorectal cancer: Short-term efficacy and impact on immune function and PD-1/PD-L1 signaling pathway
inferred← citeshttps://doi.org/10.1158/1055-9965.epi-23-1459openalex-snapshot
High Incidence of Gastric Cancer in El Salvador: A National Multisectorial Study during 2000 to 2014
inferred← citeshttps://doi.org/10.1158/1078-0432.c.6530120.v1openalex-snapshot
Data from Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-20-4691openalex-snapshot
Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
inferred← citeshttps://doi.org/10.1158/1541-7786.mcr-25-0154openalex-snapshot
The SNHG15/miR-451a/Caveolin-1 Axis Promotes Oxaliplatin Resistance in Gastric Cancer Cells by Regulating Fatty Acid β-Oxidation
inferred← citeshttps://doi.org/10.1158/2159-8290.cd-21-0888openalex-snapshot
Early Tumor–Immune Microenvironmental Remodeling and Response to First-Line Fluoropyrimidine and Platinum Chemotherapy in Advanced Gastric Cancer
inferred← citeshttps://doi.org/10.1159/000515175openalex-snapshot
Real-World Therapeutic Outcomes of S-1 Adjuvant Chemotherapy for pStage II/III Gastric Cancer in the Elderly
inferred← citeshttps://doi.org/10.1159/000531457openalex-snapshot
Efficacy of PD-1 Inhibitors in First-Line Treatment for Advanced Gastroesophageal Junction and Gastric Cancer by Subgroups: A Systematic Review and Meta-Analysis
inferred← citeshttps://doi.org/10.1159/000534145openalex-snapshot
Rare Case of Advanced Gastric Cancer Complicated with Fibrinogen Storage Disease Treated with Chemotherapy plus Immune Checkpoint Inhibitor: A Case Report
inferred← citeshttps://doi.org/10.1177/10732748221111296openalex-snapshot
Tislelizumab: A Modified Anti-tumor Programmed Death Receptor 1 Antibody
inferred← citeshttps://doi.org/10.1177/15330338221150555openalex-snapshot
Research Progress of Immunotherapy for Gastric Cancer
inferred← citeshttps://doi.org/10.1177/1756284820948773openalex-snapshot
Current status of treatment with immune checkpoint inhibitors for gastrointestinal, hepatobiliary, and pancreatic cancers
inferred← citeshttps://doi.org/10.1177/17588359221110176openalex-snapshot
Tumor vessel normalization and immunotherapy in gastric cancer
inferred← citeshttps://doi.org/10.1177/17588359221118020openalex-snapshot
Nab-paclitaxel plus S-1 versus oxaliplatin plus S-1 as first-line treatment in advanced gastric cancer: results of a multicenter, randomized, phase III trial (GAPSO study)
inferred← citeshttps://doi.org/10.1177/17588359241266156openalex-snapshot
Research progress and future directions of immune checkpoint inhibitor combination therapy in advanced gastric cancer
inferred← citeshttps://doi.org/10.1177/17588359251378698openalex-snapshot
S-1 plus oxaliplatin versus modified FOLFIRINOX for advanced pancreatic adenocarcinoma after gemcitabine plus nab-paclitaxel failure
inferred← citeshttps://doi.org/10.1186/s12876-024-03508-0openalex-snapshot
Efficacy and safety of Nivolumab in advanced gastric and gastroesophageal junction cancer: a meta-analysis of randomized controlled trials
inferred← citeshttps://doi.org/10.1186/s12885-020-06958-3openalex-snapshot
Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217)
inferred← citeshttps://doi.org/10.1186/s12885-020-07251-zopenalex-snapshot
Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial
inferred← citeshttps://doi.org/10.1186/s12885-021-08487-zopenalex-snapshot
Surgery alone, adjuvant tegafur/gimeracil/octeracil (S-1), or platinum-based chemotherapies for resectable gastric cancer: real-world experience and a propensity score matching analysis
inferred← citeshttps://doi.org/10.1186/s12885-022-10125-1openalex-snapshot
Comparison of response evaluation criteria in solid tumors and tumor regression grade in evaluating the effect of preoperative systemic therapy of gastric cancer
inferred← citeshttps://doi.org/10.1186/s12885-022-10199-xopenalex-snapshot
Are anti-PD-1-associated immune related adverse events a harbinger of favorable clinical prognosis in patients with gastric cancer?
inferred← citeshttps://doi.org/10.1186/s12885-023-10661-4openalex-snapshot
Sintilimab Plus Apatinib and Chemotherapy as Second‑/Third-Line treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a prospective, Single-Arm, phase II trial
inferred← citeshttps://doi.org/10.1186/s12885-024-12998-wopenalex-snapshot
Prognostic and predictive factors in advanced upper gastrointestinal cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis of the current evidence
inferred← citeshttps://doi.org/10.1186/s12885-025-13712-0openalex-snapshot
Optimal early endpoint for second-line or subsequent immune checkpoint inhibitors in previously treated advanced solid cancers: a systematic review
inferred← citeshttps://doi.org/10.1186/s12885-025-15207-4openalex-snapshot
Prognostic relevance of increased tumor-infiltrating lymphocytes in residual TNBC following neoadjuvant chemotherapy
inferred← citeshttps://doi.org/10.1186/s12893-020-00884-8openalex-snapshot
Clinical significance of peripheral blood-derived inflammation markers in advanced gastric cancer after radical resection
inferred← citeshttps://doi.org/10.1186/s12893-024-02504-1openalex-snapshot
Exploratory study on the impact of intraesophageal pressure on quality of life in patients following total gastrectomy: a retrospective cohort study
inferred← citeshttps://doi.org/10.1186/s12943-021-01317-7openalex-snapshot
Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades
inferred← citeshttps://doi.org/10.1186/s13045-019-0730-9openalex-snapshot
Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
inferred← citeshttps://doi.org/10.1186/s13046-023-02730-0openalex-snapshot
Predicting response to immunotherapy in gastric cancer via assessing perineural invasion-mediated inflammation in tumor microenvironment
inferred← citeshttps://doi.org/10.1186/s40001-026-04158-6openalex-snapshot
Neoadjuvant PD-1 inhibitors plus chemotherapy versus neoadjuvant chemotherapy alone in patients with resectable locally advanced gastric cancer
inferred← citeshttps://doi.org/10.1186/s40364-020-00250-zopenalex-snapshot
Recent updates on Sintilimab in solid tumor immunotherapy
inferred← citeshttps://doi.org/10.1186/s40792-024-02001-wopenalex-snapshot
Perioperative chemotherapy with nivolumab for HER2-negative locally advanced gastric cancer: a case series
inferred← citeshttps://doi.org/10.1200/edbk_321243openalex-snapshot
Where to Start and What to Do Next: The Sequencing of Treatments in Metastatic Esophagogastric Cancer
inferred← citeshttps://doi.org/10.1200/jco.21.02500openalex-snapshot
Esophagogastric Cancers: Integrating Immunotherapy Therapy Into Current Practice
inferred← citeshttps://doi.org/10.1245/s10434-023-14586-xopenalex-snapshot
Cancer-Associated Fibroblast-Derived IL-8 Upregulates PD-L1 Expression in Gastric Cancer Through the NF-κB Pathway
inferred← citeshttps://doi.org/10.1248/bpb.b22-00150openalex-snapshot
Difference in Cost-Effectiveness between First-Line and Third-Line or Later Nivolumab Therapy in Patients with HER2-Negative, Unresectable, Advanced or Recurrent Gastric or Gastro-Esophageal Junction Cancer in Japan
inferred← citeshttps://doi.org/10.12677/acm.2022.127995openalex-snapshot
Research on the Correlation between Advanced Gastric Cancer Molecule Molecular Targeted and Immune Therapy
inferred← citeshttps://doi.org/10.12677/acm.2023.13102264openalex-snapshot
Research Progress of Immune Checkpoint Inhibitors in the Treatment of Advanced Gastric Cancer
inferred← citeshttps://doi.org/10.12998/wjcc.v9.i21.5782openalex-snapshot
Research status on immunotherapy trials of gastric cancer
inferred← citeshttps://doi.org/10.1371/journal.pone.0275481openalex-snapshot
Predictors for development of oxaliplatin-induced peripheral neuropathy in cancer patients as determined by ordered logistic regression analysis
inferred← citeshttps://doi.org/10.15761/crr.1000183openalex-snapshot
Long-term survivors of metastatic gastric cancer for >5 years after chemotherapy initiation
inferred← citeshttps://doi.org/10.18632/aging.104084openalex-snapshot
Could microtubule inhibitors be the best choice of therapy in gastric cancer with high immune activity: mutant DYNC1H1 as a biomarker
inferred← citeshttps://doi.org/10.18632/aging.205652openalex-snapshot
Cancer cachexia reduces the efficacy of immune checkpoint inhibitors in cancer patients
inferred← citeshttps://doi.org/10.18632/oncotarget.27873openalex-snapshot
Oncolytic virotherapy with SOCS3 enhances viral replicative potency and oncolysis for gastric cancer
inferred← citeshttps://doi.org/10.20517/2394-4722.2021.113openalex-snapshot
Recent updates of therapeutic strategy of esophagogastric junction adenocarcinoma
inferred← citeshttps://doi.org/10.21037/apm-19-430aopenalex-snapshot
Predictors for the clinical benefit of anti-PD-1/PD-L1 therapy in advanced gastroesophageal cancer: a meta-analysis of clinical trials
inferred← citeshttps://doi.org/10.21037/apm.2020.04.26openalex-snapshot
The efficacy and safety of capecitabine-based versus S-1-based chemotherapy for metastatic or recurrent gastric cancer: a systematic review and meta-analysis of clinical randomized trials
inferred← citeshttps://doi.org/10.21037/atm-20-4699openalex-snapshot
Combination of immunotherapy with chemotherapy in first line treatment of metastatic gastric cancer? Too much, too little or just right?
inferred← citeshttps://doi.org/10.21037/atm-20-4725openalex-snapshot
Safety and preliminary signs of efficacy with the combination of pembrolizumab plus oxaliplatin and S-1 in Japanese gastric cancer patients
inferred← citeshttps://doi.org/10.21037/atm-21-434openalex-snapshot
Locally advanced gastroesophageal junction cancer with pathological complete response to neoadjuvant therapy: a case report and literature review
inferred← citeshttps://doi.org/10.21037/atm-22-1064openalex-snapshot
Current treatments and outlook in adenocarcinoma of the esophagogastric junction: a narrative review
inferred← citeshttps://doi.org/10.21037/atm.2020.03.110openalex-snapshot
Evolving treatment paradigms in esophageal cancer
inferred← citeshttps://doi.org/10.21037/atm.2020.03.54openalex-snapshot
Differential microRNA expression profiles associated with microsatellite status reveal possible epigenetic regulation of microsatellite instability in gastric adenocarcinoma
inferred← citeshttps://doi.org/10.21037/cco-23-13openalex-snapshot
Brave new world—new and emerging treatments for gastric cancer
inferred← citeshttps://doi.org/10.21037/jgo-21-897openalex-snapshot
Efficacy and safety of camrelizumab in combination with trastuzumab and chemotherapy as the first-line treatment for patients with HER2-positive advanced gastric cancer
inferred← citeshttps://doi.org/10.21037/jgo-22-281openalex-snapshot
Immune-related adverse events and prognosis in patients with upper gastrointestinal cancer treated with nivolumab
inferred← citeshttps://doi.org/10.21037/jgo-22-499openalex-snapshot
Risk factors and efficacy outcomes of early-onset severe neutropenia due to paclitaxel or nanoparticle albumin-bound paclitaxel combined with ramucirumab in advanced gastric cancer: a multicenter retrospective cohort study
inferred← citeshttps://doi.org/10.21037/jgo-23-464openalex-snapshot
A narrative review of the evolving landscape of the management of metastatic gastric cancer: the role of targeted therapies
inferred← citeshttps://doi.org/10.21037/jgo-23-511openalex-snapshot
Two autopsied gastric cancer cases of rare drug-induced pneumonia associated with nivolumab plus S-1 and oxaliplatin: a case report
inferred← citeshttps://doi.org/10.21147/j.issn.1000-9604.2020.03.02openalex-snapshot
Immune checkpoint inhibitors for treatment of advanced gastric or gastroesophageal junction cancer: Current evidence and future perspectives
inferred← citeshttps://doi.org/10.21203/rs.3.rs-1557463/v1openalex-snapshot
Comparative efficacy and tolerability of target agents and immune checkpoint inhibitors in combination with chemotherapy as First-line treatment for advanced gastric cancer: A Bayesian network meta-analysis
inferred← citeshttps://doi.org/10.21203/rs.3.rs-2387247/v1openalex-snapshot
Tumor recurrence after pathologic complete response in locally advanced gastric cancer after neoadjuvant therapy: case report and literature review
inferred← citeshttps://doi.org/10.21203/rs.3.rs-4119504/v1openalex-snapshot
Safety assessment of S-1: Real-world adverse event analysis from the FAERS database
inferred← citeshttps://doi.org/10.2139/ssrn.5235089openalex-snapshot
First-Line Tislelizumab Combined with Bevacizumab and CAPOX for Locally Advanced or Metastatic Gastroesophageal Adenocarcinomas with PD-L1 CPS <5: A Phase II Single-Arm Study
inferred← citeshttps://doi.org/10.2147/ijgm.s509902openalex-snapshot
Impact of the SOX Regimen on Immune Function and Tumor Markers in Advanced Gastric Cancer
inferred← citeshttps://doi.org/10.2147/ott.s152513openalex-snapshot
Pembrolizumab for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction cancer: an evidence-based review of place in therapy
inferred← citeshttps://doi.org/10.2147/ott.s221436openalex-snapshot
Durable Response After Combination Of Concurrent Chemoradiotherapy And Anti-PD-1 Therapy In HER2-Negative Advanced Gastric Adenocarcinoma: A Case Report
inferred← citeshttps://doi.org/10.2147/ott.s239789openalex-snapshot
Circ-OXCT1 Suppresses Gastric Cancer EMT and Metastasis by Attenuating TGF-β Pathway Through the Circ-OXCT1/miR-136/SMAD4 Axis
inferred← citeshttps://doi.org/10.2147/ott.s246412openalex-snapshot
Current Molecular Targeted Agents for Advanced Gastric Cancer
inferred← citeshttps://doi.org/10.2147/ott.s282718openalex-snapshot
Targeting FGFR2 Positive Gastroesophageal Cancer: Current and Clinical Developments
inferred← citeshttps://doi.org/10.2147/ott.s284092openalex-snapshot
Complete Response to the Sequential Treatment with Regorafenib Followed by PD-1 Inhibitor in a Sorafenib-Refractory Hepatocellular Carcinoma Patient
inferred← citeshttps://doi.org/10.21518/2079-701x-2020-20-15-21openalex-snapshot
Prospects of application of inhibitors of PD-1/PD-L1 checkpoints in malignant tumors of the stomach and esophagogastric junction
inferred← citeshttps://doi.org/10.2174/0113862073386878250801103600openalex-snapshot
Knockdown of NFS1 and Oxaliplatin Combination Induces Pyroptosis via the Caspase-3/GSDME Pathway in Gastric Cancer Cells
inferred← citeshttps://doi.org/10.2174/0115680096314855240619181909openalex-snapshot
Envafolimab Inhibits the Growth of Gastric Cancer Cells with Low PD-L1 Expression through the DDX20/NF-κB/TNF-α Signaling Pathway
inferred← citeshttps://doi.org/10.2174/0115680096319027240820055043openalex-snapshot
The Therapeutic Potential of Targeting Tumor Microenvironment and Modulation of Immunotherapy in Gastrointestinal Cancer
inferred← citeshttps://doi.org/10.21873/anticanres.14547openalex-snapshot
A Gemcitabine Plus 5-Fluorouracil Combination Inhibits Gastric-Cancer Liver Metastasis in a PDOX Model: A Novel Treatment Strategy
inferred← citeshttps://doi.org/10.21873/anticanres.15781openalex-snapshot
Neutrophil-to-Lymphocyte Ratio to Predict the Efficacy of Immune Checkpoint Inhibitor in Upper Gastrointestinal Cancer
inferred← citeshttps://doi.org/10.21873/invivo.12506openalex-snapshot
Impact of Immune-related Adverse Events on Nivolumab Efficacy in Patients With Upper Gastrointestinal Cancer
inferred← citeshttps://doi.org/10.2217/bmm-2023-0052openalex-snapshot
Prognostic Value of the Lung Immune Prognostic Index for HER-2-Negative Metastatic Gastric Cancer
inferred← citeshttps://doi.org/10.2217/fon-2020-0298openalex-snapshot
WJOG10517G: A Multicenter Phase II Study of mFOLFOX6 in Gastric Cancer Patients with Severe Peritoneal Metastases
inferred← citeshttps://doi.org/10.2217/fon-2020-0829openalex-snapshot
Progress and Prospects of Immune Checkpoint Inhibitors in Advanced Gastric Cancer
inferred← citeshttps://doi.org/10.2217/fon-2021-0176openalex-snapshot
KEYNOTE-859: a Phase III Study of Pembrolizumab Plus Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma
showing the first 200 of 311 · page through all 311
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.